Vascular NADPH oxidases as drug targets for novel antioxidant strategies

Guzik, T. J. and Harrison, D. G. (2006) Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discovery Today, 11(11-12), pp. 524-533. (doi: 10.1016/j.drudis.2006.04.003) (PMID:16713904)

Full text not currently available from Enlighten.


Reactive oxygen species (ROS) play important roles in the pathogenesis of cardiovascular disease. Surprisingly, large clinical trials have shown that ROS scavenging by antioxidant vitamins is ineffective or harmful. Therefore, prevention of ROS formation, by targeting specific sources of superoxide anion and other ROS, might prove beneficial. Potential targets include the NADPH oxidases (Nox enzymes), xanthine oxidase, endothelial nitric oxide synthase and mitochondrial oxidases. Nox enzymes play a central role because they can regulate other enzymatic sources of ROS. Statins, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists block upstream signaling of Nox activation, which contributes to their clinical effectiveness. Here, we discuss novel possibilities where drugs that directly inhibit Nox activation could successfully inhibit oxidative stress.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Harrison, Professor David and Guzik, Professor Tomasz
Authors: Guzik, T. J., and Harrison, D. G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Drug Discovery Today
ISSN (Online):1878-5832
Published Online:19 May 2006

University Staff: Request a correction | Enlighten Editors: Update this record